Today we’re proud to announce that we’ve received approvals to permit Tilray to export medical cannabis to New Zealand.

Medical cannabis in New Zealand will be available to patients with special authorization from the Ministry of Health. Tilray will supply Middlemore Hospital in Auckland with precisely formulated medical cannabis oil containing tetrahydrocannabinol (THC) and cannabidiol (CBD). The first shipment of Tilray products is expected to arrive in Auckland by the end of February.

Tilray currently supplies pharmaceutical-grade medical cannabis products—including whole flower and extracts—to thousands of patients, physicians, pharmacies, hospitals, governments and researchers around the world. We became the first medical cannabis producer in North America to be certified in accordance with the European Medicines Agency’s (EMA) Good Manufacturing Practice (GMP) standards in December 2016. GMP certification is the most rigorous standard that manufacturers of medical products must meet in their production processes, and it provides regulators and health care providers in countries new to medical cannabis with certainty that Tilray products are the safe and smart choice.

GMP certification is enabling us to expand international distribution of its products for commercial, clinical research and compassionate purposes. In 2016, Tilray made history by becoming the first company to legally export medical cannabis products from North America to Australia and the European Union. The company is currently partnering with hospitals and universities on three clinical trials focused on pediatric epilepsy, post-traumatic stress disorder (PTSD), and chemotherapy-induced nausea and vomiting (CINV).